These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 37766145)
1. An Efficient and Scalable Method for the Production of Immunogenic SARS-CoV-2 Virus-like Particles (VLP) from a Mammalian Suspension Cell Line. Hirschberg S; Ghazaani F; Ben Amor G; Pydde M; Nagel A; Germani S; Monica L; Schlör A; Bauer H; Hornung J; Voetz M; Dwai Y; Scheer B; Ringel F; Kamal-Eddin O; Harms C; Füner J; Adrian L; Pruß A; Schulze-Forster K; Hanack K; Kamhieh-Milz J Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766145 [TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells. Alpuche-Lazcano SP; Stuible M; Akache B; Tran A; Kelly J; Hrapovic S; Robotham A; Haqqani A; Star A; Renner TM; Blouin J; Maltais JS; Cass B; Cui K; Cho JY; Wang X; Zoubchenok D; Dudani R; Duque D; McCluskie MJ; Durocher Y Commun Med (Lond); 2023 Aug; 3(1):116. PubMed ID: 37612423 [TBL] [Abstract][Full Text] [Related]
3. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus. Garg H; Sedano M; Plata G; Punke EB; Joshi A J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019 [TBL] [Abstract][Full Text] [Related]
4. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2. Resch MD; Wen K; Mazboudi R; Mulhall Maasz H; Persaud M; Garvey K; Gallardo L; Gottlieb P; Alimova A; Khayat R; Morales J; Bielefeldt-Ohmann H; Bowen RA; Galarza JM Vaccines (Basel); 2022 Nov; 10(12):. PubMed ID: 36560407 [TBL] [Abstract][Full Text] [Related]
6. Optimized production and fluorescent labeling of SARS-CoV-2 virus-like particles. Gourdelier M; Swain J; Arone C; Mouttou A; Bracquemond D; Merida P; Saffarian S; Lyonnais S; Favard C; Muriaux D Sci Rep; 2022 Aug; 12(1):14651. PubMed ID: 36030323 [TBL] [Abstract][Full Text] [Related]
7. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants. van Oosten L; Altenburg JJ; Fougeroux C; Geertsema C; van den End F; Evers WAC; Westphal AH; Lindhoud S; van den Berg W; Swarts DC; Deurhof L; Suhrbier A; Le TT; Torres Morales S; Myeni SK; Kikkert M; Sander AF; de Jongh WA; Dagil R; Nielsen MA; Salanti A; Søgaard M; Keijzer TMP; Weijers D; Eppink MHM; Wijffels RH; van Oers MM; Martens DE; Pijlman GP mBio; 2021 Oct; 12(5):e0181321. PubMed ID: 34634927 [TBL] [Abstract][Full Text] [Related]
8. Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System. Xu R; Shi M; Li J; Song P; Li N Front Bioeng Biotechnol; 2020; 8():862. PubMed ID: 32850726 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits. O'Kennedy MM; Abolnik C; Smith T; Motlou T; Goosen K; Sepotokele KM; Roth R; du Preez I; Truyts A; Stark HC; Magwaza M; Mahanjana O; Verschoor JA; Moore PL; Lemmer Y Vaccine; 2023 Mar; 41(13):2261-2269. PubMed ID: 36868876 [TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Virus-like Particles Produced by a Single Recombinant Baculovirus Generate Anti-S Antibody and Protect against Variant Challenge. Sullivan E; Sung PY; Wu W; Berry N; Kempster S; Ferguson D; Almond N; Jones IM; Roy P Viruses; 2022 Apr; 14(5):. PubMed ID: 35632656 [TBL] [Abstract][Full Text] [Related]
11. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles. Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098 [TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History. Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006 [TBL] [Abstract][Full Text] [Related]
18. Chimeric Virus-like Particles of Universal Antigen Epitopes of Coronavirus and Phage Qβ Coat Protein Trigger the Production of Neutralizing Antibodies. Guo Y; Guo R; Ma Y; Chang W; Ming S; Yang G; Guo Y Curr Top Med Chem; 2021 Oct; 21(14):1235-1250. PubMed ID: 34145995 [TBL] [Abstract][Full Text] [Related]
19. Rapid screening and scaled manufacture of immunogenic virus-like particles in a tobacco BY-2 cell-free protein synthesis system. Armero-Gimenez J; Wilbers R; Schots A; Williams C; Finnern R Front Immunol; 2023; 14():1088852. PubMed ID: 36776898 [TBL] [Abstract][Full Text] [Related]